Investors / United States / Adjuvant Capital
Adjuvant Capital
Venture capital · New York City, NY, United States · North America
Adjuvant Capital is a venture capital firm that finances life science technologies addressing high-burden public health challenges. It makes preferred equity investments in technologies that have demonstrated safety and efficacy in humans, aiming to accelerate global availability of medical innovations.
Invests inHealthcare & Biotech
In its own wordsglobal healthlife sciencesinfectious diseasesmaternal healthantimicrobial resistanceimpact investing
Your fit with Adjuvant Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsAdjuvant Capital lists 14 checked portfolio companies on its own site and is named in 1 funding round, 1 of them as lead. Its most frequent entry is Series B, 100% of the companies with a known first round. Its largest themes are Healthcare & Biotech (93%) and Food & Agriculture (7%). 44% of its companies are based in United States. It invests most often alongside British International Investment, Pureos Bioventures and RA Capital.
Counts come from funding rounds that name Adjuvant Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Adjuvant Capital's whole history. Rounds on record name 1 company; its own site lists 14. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundAdjuvant Capital does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 0% |
| Series B | 100% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 1 |
| '26 | 0 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 36th | 14 companies |
| Recent activity | 46th | 0 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 70th | 7% of companies confirmed by a round |
| Sector focus | 96th | 93% in its largest sector |
| Reach | 78th | 5 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| British International Investment | 8 |
| Pureos Bioventures | 2 |
| RA Capital | 2 |
| Atinum Investment | 1 |
| Better Ventures | 1 |
| BioRock Ventures | 1 |
| Brace Pharma Capital | 1 |
| Buff Gold Ventures | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers14100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 93% | 15% |
| Food & Agriculture | 7% | 3% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with British International Investment
Compare Adjuvant Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Adjuvant Capital| Date | Company | Stage |
|---|---|---|
| 22 Oct 2025 | Series B Led |
Round details for Adjuvant Capital
Amounts, full round histories and every co-investor in Adjuvant Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
14 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Portfolio page | ||||
| AN2 Therapeutics develops boron-based medicines for various diseases, including polycythemia vera, Chagas disease, and certain types of cancer. | Healthcare & Biotech | Portfolio page | ||
| Antiva Biosciences is developing a novel topical therapeutic for the treatment of oncogenic human papillomavirus infections and pre-cancerous cervical lesions | Healthcare & Biotech | Portfolio page | ||
| Chromacode provides genomic solutions through its High-Definition PCR multiplexing platform and related products | Healthcare & Biotech | Portfolio page | ||
| Codagenix is engineering viruses to transform global health | Healthcare & Biotech | Portfolio page | ||
| Evofem Biosciences develops and commercializes products for women's sexual and reproductive healthcare, including a hormone-free contraceptive vaginal gel called Phexxi. | Healthcare & Biotech | Portfolio page | ||
| Frontier Nutrition provides innovative, nutritious, and delicious fortified snacks to low-income communities worldwide. | Food & AgricultureHealthcare & Biotech | Portfolio page | ||
| InDevR offers analytical solutions to expedite the development, optimization, and production of multiple types of vaccines. | Healthcare & Biotech | Portfolio page | ||
| LakeShore Biopharma is a biopharmaceutical company that produces, sells, and researches vaccines and other immunological products, focusing on infectious diseases | Healthcare & Biotech | Portfolio page | ||
| LimmaTech Biologics is developing innovative vaccines against antimicrobial resistant pathogens | Healthcare & Biotech | Portfolio page | ||
| Memo Therapeutics develops therapeutic antibodies to treat viral infections and cancer. | Healthcare & Biotech | Portfolio page | ||
| MinervaX is developing a prophylactic vaccine against Group B Streptococcus | Healthcare & Biotech | Portfolio page | ||
| Quantoom provides a unified RNA platform for designing, producing, and delivering RNA candidates | Healthcare & Biotech | Portfolio page | ||
| VitriVax is a formulation technology company engineering innovative solutions to maximize global accessibility and utility of human vaccines | Healthcare & Biotech | Oct 2025Series B | Page + round |
About this data
site last read 5 Nov 2026- Site
- adjuvantcapital.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 22 Oct 2025
- Companies checked
- 14
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Adjuvant Capital's profile as data
Pull Adjuvant Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/adjuvantcapital.com
# also
GET /v1/firms/adjuvantcapital.com/portfolio
GET /v1/firms/adjuvantcapital.com/coinvestors
GET /v1/firms/adjuvantcapital.com/news